Patient Immunotherapy Summit: Lung Cancer Brief
Dr. Thomas Urban Marron, MD, PhD, stands as a notable figure in lung cancer research and treatment, currently affiliated with the Icahn School of Medicine at Mount Sinai. His expertise in both medicine and research positions him as a distinguished authority in the field. Dr. Marron's notable role as a CRI Clinical Innovator reflects his commitment to driving innovation in cancer immunotherapy. Through his work, he contributes significantly to advancing our understanding of lung cancer and developing novel approaches to treatment, marking him as a key influencer in the ongoing efforts to combat this complex disease. Dr. Marron's dual role as a clinician and innovator underscores his dedication to bridging the gap between cutting-edge research and practical, patient-centered care in the realm of lung cancer.
Established in 1953, the Cancer Research Institute (CRI) is a 501(c)(3) nonprofit organization dedicated to harnessing our immune system’s power to control and potentially cure all cancers. Our mission: Save more lives by fueling the discovery and development of powerful immunotherapies for all types of cancer. To accomplish this, we rely on donor support and collaborative partnerships to fund and carry out the most innovative clinical and laboratory research around the world, support the next generation of the field’s leaders, and serve as the trusted source of information on immunotherapy for cancer patients and their caregivers. https://www.cancerresearch.org
Cancer Research Institute is a registered 501(c)(3) nonprofit under EIN 13-1837442. Donations are tax-deductible to the fullest extent allowable under the law.